Title : Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up.

Pub. Date : 2020 Sep 30

PMID : 32839355






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. ferric carboxymaltose erythropoietin Homo sapiens
2 The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). ferric carboxymaltose erythropoietin Homo sapiens
3 The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). ferric carboxymaltose erythropoietin Homo sapiens
4 Conclusion: During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. ferric carboxymaltose erythropoietin Homo sapiens